SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that European Urology Oncology published results of a clinical study demonstrating the implications of implementing Bladder EpiCheck® in conjunction with standard-of-care (SoC) white light cystoscopy (WLC) for non-muscle invasive bladder cancer (NMIBC) surveillance in high-grade recurrence. The article was published online in European
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
